BR112017023798A2 - domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana - Google Patents

domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana

Info

Publication number
BR112017023798A2
BR112017023798A2 BR112017023798A BR112017023798A BR112017023798A2 BR 112017023798 A2 BR112017023798 A2 BR 112017023798A2 BR 112017023798 A BR112017023798 A BR 112017023798A BR 112017023798 A BR112017023798 A BR 112017023798A BR 112017023798 A2 BR112017023798 A2 BR 112017023798A2
Authority
BR
Brazil
Prior art keywords
membrane
type iii
fibronectin type
iii domains
prostate antigen
Prior art date
Application number
BR112017023798A
Other languages
English (en)
Inventor
Klein Donna
O'neil Karyn
Hyun Linus
Diem Michael
Cardoso Rosa
GOLDBERG Shalom
Jacobs Steven
Spinka-Doms Tracy
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112017023798A2 publication Critical patent/BR112017023798A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a domínios fn3 de ligação a psma, seus conjugados, nucleotídeos isolados codificando as moléculas, vetores, células hospedeiras, e a métodos para sua preparação que são úteis na geração de moléculas terapêuticas, bem como ao tratamento e ao diagnóstico de doenças e distúrbios.
BR112017023798A 2015-05-06 2016-05-06 domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana BR112017023798A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562157772P 2015-05-06 2015-05-06
PCT/US2016/031295 WO2016179534A2 (en) 2015-05-06 2016-05-06 Prostate specific membrane antigen binding fibronectin type iii domains

Publications (1)

Publication Number Publication Date
BR112017023798A2 true BR112017023798A2 (pt) 2018-10-16

Family

ID=57217949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023798A BR112017023798A2 (pt) 2015-05-06 2016-05-06 domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana

Country Status (13)

Country Link
US (2) US10844111B2 (pt)
EP (1) EP3292222A4 (pt)
JP (2) JP7366518B2 (pt)
KR (1) KR102625793B1 (pt)
CN (1) CN107849116A (pt)
AU (2) AU2016258174B2 (pt)
BR (1) BR112017023798A2 (pt)
CA (1) CA2985138A1 (pt)
EA (1) EA201792441A2 (pt)
HK (1) HK1253005A1 (pt)
IL (1) IL255425B2 (pt)
MA (1) MA42060A (pt)
WO (1) WO2016179534A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
CA3046963A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
EP3655026A4 (en) * 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
EP3672611A4 (en) 2017-08-25 2021-07-14 Janssen Biotech, Inc. TYPE III DOMAINS OF FIBRONECTIN BINDER FCyRII, THEIR CONJUGATES AND MULTISPECIFIC MOLECULES INCLUDING THEM
AU2018386010A1 (en) * 2017-12-13 2020-05-14 Janssen Biotech, Inc. Immortalized car-T cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
WO2019173636A1 (en) * 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
JP7361727B2 (ja) 2018-05-24 2023-10-16 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合剤及びその使用
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201820325D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2020208083A1 (en) * 2019-04-10 2020-10-15 Navigo Proteins Gmbh Novel psma specific binding proteins for cancer diagnosis and treatment
JP2022529985A (ja) 2019-04-19 2022-06-27 ヤンセン バイオテツク，インコーポレーテツド 抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
BR112023021325A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Domínios de fibronectina tipo iii de ligação a cd71
KR20240053607A (ko) * 2021-08-27 2024-04-24 얀센 바이오테크 인코포레이티드 항-psma 방사성 접합체 및 이의 용도
JP2024535712A (ja) 2021-08-27 2024-10-02 ヤンセン バイオテツク，インコーポレーテツド 抗ｐｓｍａ抗体及びその使用
WO2023135944A1 (ja) 2022-01-11 2023-07-20 住友電気工業株式会社 マルチコア光ファイバの製造方法及びマルチコア光ファイバ
CN114940710B (zh) * 2022-06-07 2023-09-26 恺佧生物科技(上海)有限公司 一种提高重组人psma蛋白表达的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
AU2002213251B2 (en) * 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA03010328A (es) 2001-05-11 2004-02-17 Guilford Pharm Inc Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2004022746A1 (en) 2002-09-06 2004-03-18 Isogenica Limited In vitro peptide expression libraray
US8470332B2 (en) * 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2009085468A2 (en) 2007-12-19 2009-07-09 Centocor, Inc. Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
AU2009308935B2 (en) * 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
PT2571531T (pt) 2010-04-30 2016-08-31 Janssen Biotech Inc Composições do domínio da fibronectina estabilizadas, métodos e utilizações
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
BR112013032630B1 (pt) * 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX2016007533A (es) * 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
AU2016258115A1 (en) * 2015-05-06 2017-11-23 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Also Published As

Publication number Publication date
IL255425B2 (en) 2023-10-01
IL255425A0 (en) 2017-12-31
KR102625793B1 (ko) 2024-01-15
US10844111B2 (en) 2020-11-24
JP7307133B2 (ja) 2023-07-11
EP3292222A2 (en) 2018-03-14
KR20180002780A (ko) 2018-01-08
EP3292222A4 (en) 2018-10-17
JP2018515087A (ja) 2018-06-14
IL255425B1 (en) 2023-06-01
HK1253005A1 (zh) 2019-06-06
JP7366518B2 (ja) 2023-10-23
US20210147510A1 (en) 2021-05-20
US12054534B2 (en) 2024-08-06
AU2016258174B2 (en) 2022-01-20
CN107849116A (zh) 2018-03-27
AU2016258174A1 (en) 2017-11-23
WO2016179534A2 (en) 2016-11-10
US20160326232A1 (en) 2016-11-10
EA201792441A2 (ru) 2018-06-29
MA42060A (fr) 2018-03-14
CA2985138A1 (en) 2016-11-10
AU2022202637A1 (en) 2022-05-12
JP2022002526A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
BR112017023798A2 (pt) domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana
NI201500070A (es) Moleculas de union del dominio de egfr y c-met-fibronectina de tipo iii
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
BR112018004725A2 (pt) método para a produção de oligossacarídeos de leite humano em hospedeiros microbianos com importação/exportação modificada e célula hospedeira microbiana
BR112015021819A2 (pt) Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19
PH12015501672A1 (en) Binding molecules for bcma and cd3
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
PE20151146A1 (es) Proteinas de union al antigeno bcma
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
BR112017005997A2 (pt) método
BR112015023472A2 (pt) método de produção de um produto químico, método de bioprodução de um produto químico, organismo geneticamente modificado e produto
BR112017013956A2 (pt) proteínas de fusão de citocinas
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112016013845A2 (pt) Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
PE20150346A1 (es) Anticuerpos de anti-transglutaminasa 2
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
BR112016002317A2 (pt) métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]